Effects of Trimetazidine on Right Ventricular Function and Ventricular Remodeling in Patients with Pulmonary Artery Hypertension: A Randomised Controlled Trial.
Hugo E VerdejoAdolfo RojasCamila López-CrisostoFernando BaraonaLuigi GabrielliVinicius Maracaja-CoutinhoMario ChiongSergio LavanderoPablo F CastroPublished in: Journal of clinical medicine (2023)
A short course of trimetazidine is safe and well-tolerated on PAH patients, and it is associated with significant increases in the 6MWT and minor but significant improvement in RV remodeling. The therapeutic potential of this drug should be evaluated in larger clinical trials.
Keyphrases
- pulmonary artery
- clinical trial
- coronary artery
- end stage renal disease
- pulmonary hypertension
- pulmonary arterial hypertension
- mycobacterium tuberculosis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- heart failure
- prognostic factors
- randomized controlled trial
- peritoneal dialysis
- emergency department
- study protocol
- double blind
- arterial hypertension